OneSource Specialty Pharma
OneSource Specialty Pharma Share Price Chart
OneSource Specialty Pharma last traded at ₹1,462.30 (2026-10-13). Over the past month the stock moved -5.5%, three months the stock moved -19.0%, year the stock moved -18.3%. Its closing range over 52 weeks is ₹1,119.90 – ₹1,854.10, with the latest close 21.1% below the high.
Closing prices up to 2026-10-13.
About OneSource Specialty Pharma
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio logical drug products in various injectable formats. It also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics[1]
Business Overview:[1] OSSPL is a subsidiary of Strides Pharma Ltd. The company is a Contract Development and Manufacturing Organisation that caters to several biopharma and biotech companies. It covers the entire CDMO value chain, from clinical development to technology transfer to commercial manufacture and regulatory assistance.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), OneSource Specialty Pharma reported sales of ₹449.00 crore (+37.3%) and net profit of ₹25.00 crore, compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 449.00 | 123.00 | 27.00 | 25.00 | 2.18 |
| Mar 2026 | 428.00 | 92.00 | 21.00 | 5.00 | 0.40 |
| Dec 2025 | 290.00 | 17.00 | 6.00 | -89.00 | -7.74 |
| Sep 2025 | 376.00 | 106.00 | 28.00 | 10.00 | 0.92 |
| Jun 2025 | 327.00 | 88.00 | 27.00 | 0.00 | -0.02 |
| Mar 2025 | 426.00 | 183.00 | 43.00 | 98.00 | 8.61 |
| Dec 2024 | 393.00 | 142.00 | 36.00 | -69.00 | -6.02 |
| Sep 2024 | 334.00 | 77.00 | 23.00 | -42.00 | – |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +882.4% | +601.8% | +483.6% | +12.0% | +12.6% | -26.2% | +0.5% | +37.3% |
| Operating profit growth | – | – | – | +37.5% | +37.7% | -88.0% | -49.7% | +39.8% |
| Net profit growth | – | – | – | – | – | – | -94.9% | – |
| EPS growth | – | – | – | – | – | – | -95.4% | – |
| OPM % | 23.0% | 36.0% | 43.0% | 27.0% | 28.0% | 6.0% | 21.0% | 27.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), OneSource Specialty Pharma reported sales of ₹1,422.00 crore (-1.6%) and net profit of ₹-74.00 crore, compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 1,422 | 304.00 | 21.00 | -74.00 | -6.44 |
| Mar 2025 | 1,445 | 467.00 | 32.00 | -18.00 | -1.57 |
| Mar 2024 | 172.00 | -82.00 | -48.00 | -391.00 | – |
| Mar 2023 | 39.00 | -161.00 | -415.00 | -800.00 | – |
| Mar 2022 | 128.00 | -4.00 | -3.00 | -231.00 | – |
| Mar 2021 | 21.00 | -71.00 | -334.00 | -121.00 | – |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales growth | +509.5% | -69.5% | +341.0% | +740.1% | -1.6% |
| Operating profit growth | – | – | – | – | -34.9% |
| Net profit growth | – | – | – | – | – |
| EPS growth | – | – | – | – | – |
| OPM % | -3.0% | -415.0% | -48.0% | 32.0% | 21.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for OneSource Specialty Pharma.
Get Free AI Stock Analysis FREE →Latest News
-
India Ratings and Research upgrades LT rating of Onesource Specialty Pharma to 'A' - Business Standard
-
India Ratings and Research upgrades LT rating of Onesource Specialty Pharma to 'A' - Business Standard
-
Buy Onesource Specialty Pharma; target of Rs 2400: ICICI Securities - Moneycontrol.com
-
Onesource Specialty Pharma gains after Q1 swings to profit of Rs 25 cr - Business Standard
-
OneSource Specialty Pharma reports consolidated net profit of Rs 25.00 crore in the June 2026 quarter - Business Standard
-
OneSource Specialty Pharma to discuss Q1FY27 results on Jul 25 - scanx.trade
-
OneSource Specialty Pharma to discuss Q1FY27 results on Jul 25 - scanx.trade
-
OneSource Specialty Pharma ties up with Germany’s Formycon for Biosimilar manufacturing - BusinessLine
-
OneSource Specialty Pharma partners with Formycon AG to manufacture biosimilars - The Economic Times
-
ONESOURCE enters into manufacturing partnership with Formycon AG - Business Standard
Frequently Asked Questions
What is OneSource Specialty Pharma's current stock price?
OneSource Specialty Pharma shares were last quoted at ₹1,462.30 (+0.1% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of OneSource Specialty Pharma?
OneSource Specialty Pharma has a price-to-earnings (P/E) ratio of 385.78 and a price-to-book (P/B) ratio of 3.13. The industry P/E is 53.33.
What is the 52-week high and low of OneSource Specialty Pharma?
The 52-week high of OneSource Specialty Pharma is ₹1,924.00 and the 52-week low is ₹1,075.00.
What is the market cap of OneSource Specialty Pharma?
The market capitalisation of OneSource Specialty Pharma is about ₹18,359.13 crore.
How did OneSource Specialty Pharma perform in its latest quarterly results?
In the latest quarter (Jun 2026), OneSource Specialty Pharma reported sales of ₹449.00 crore (+37.3%) and net profit of ₹25.00 crore, compared with the same quarter last year.
Is OneSource Specialty Pharma a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, OneSource Specialty Pharma has a 3-year ROE of -2.00%, 3-year profit growth of 24.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in OneSource Specialty Pharma?
Promoters hold about 30.48% of OneSource Specialty Pharma.
Which sector does OneSource Specialty Pharma belong to?
OneSource Specialty Pharma belongs to the Pharmaceuticals & Drugs sector.